1Seeff LB,Curto TM,Szabo G,et ah HALT-C Trial Group Herbal product use by persons enrolled in the hepatitis C Antiviral Long- Term Treatment Against Cirrhosis ( HALT-C ) Trial. Hepatology, 2008, 47:605- 612.
2Anna DP, Antonella S, Maddalena DI, et al. Herbal Products: Benefits, Limits, and Applications in Chronic Liver Disease. Evidence-Based Complementary and Alternative Medicine. Evidence-Based Complementary and Alternative Medicine, 2012: 1-19.
3Kim MS, Liu DQ, Strauss JR,et al. Metabolism and disposition of gemfibrozil in wistar and multidrug resistance-associated protein 2- deficient TR rats. Xenobiotica, 2003, 33 : 1027-1042.
4Morazzoni P, Magistretti MJ, Giachetti C, et al. Comparative bioavailability of silipide a new flavanolignan complex in rats. European Journal of Drug Metabolism and Pharmacokinetics, 1992,17:39-44.
5Miranda SR, Lee JK, Brouwer KL, et aI. Hepatic metabolism and biliary excretion of silymarin flavonolignans in isolated perfused rat livers: role of multidrug resistanceassociated protein 2 (abec2). Drug Metabolism and Disposition, 2008, 36: 2219-2226.
6Scbandalik R, Gatti G, Perueca E. Pharmaeokinetics of silybin in bile flowing administration of silipide and silymarin in cholecysteetomy patients. ArzneimittebForsehung, 1992, 42: 964-968.
7Schrieber SJ, Wen Z, Vourvahis M, et al. The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic fatty liver disease and correlates with plasma caspase- 3/7activity. Drug metabolism and disposition: the biological fate of chemicals, 2008, 36: 1909-1916.
8Stephen J, Chihiro M, Volker L, et al. Identification of hepatoprotective flavonolignans from silymarin. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107: 5995-5999.
9Kida K, Suzuki M, Matsumoto N, et al. Identification of biliary metabolites of (-)-epiga lloeatechin gallate in rats. Journal of Agricultural and Food Chemstry, 2000, 48: 4151-4155.
10Jones CK, Brady AN, Davis AA, et al. Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. The Journal of Neuroscience, 2008, 28: 10422-10433.